Cancer mortality and senescence: Is redox therapy an option?
Genes & Development · 2025
DOI: 10.1101/gad.353129.125 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes & Development, 2025. Verfasst von Shan Kuang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA. Hauptthemen laut MEDLINE: Cellular Senescence, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Patient genomics and mouse functional genetics have revealed that senescence is a barrier to metastatic progression of prostate cancer. Many efforts focus on eliminating senescent cells, whereas others aim to elucidate distinct characteristics that set them apart from normal and aging cells. Here, we discuss how exploration of the redox state of senescent cells could help define new markers and pro-oxidant vulnerabilities, drawing analogy to what is known about the redox sensitivity of proliferating cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA trotman@cshl.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Kuang, S., Swamynathan, M. M., & Trotman, L. C. (2025). Cancer mortality and senescence: Is redox therapy an option?. Genes & Development. https://doi.org/10.1101/gad.353129.125
Vancouver
Kuang S, Swamynathan MM, Trotman LC. Cancer mortality and senescence: Is redox therapy an option?. Genes & Development. 2025. doi:10.1101/gad.353129.125
BibTeX
@article{Kuang2025,
author = {Kuang, Shan and Swamynathan, Manojit M and Trotman, Lloyd C},
title = {Cancer mortality and senescence: Is redox therapy an option?},
journal = {Genes & Development},
year = {2025},
doi = {10.1101/gad.353129.125}
}
EUVIMED